Harvard Bioscience (HBIO)Director bought ~$62K

~$62K

Approx. value · 13K sh @ $4.99

24K

Holds after · shares reported

Traded

Mar 16, 2026

Filed

Mar 18, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Dec 12, 2025Federal contract · $258K obligatedDepartment of Defense awarded HARVARD BIOSCIENCE INC: $258K obligated to date
2. Dec 15, 2025Federal contract · $23K obligatedDepartment of Defense awarded HARVARD BIOSCIENCE INC: $23K obligated to date
3. Jan 14, 2026Federal contract · $22K obligatedDepartment of Defense awarded HARVARD BIOSCIENCE INC: $22K obligated to date
4. Jan 19, 2026Company filing · Form 8-K · Bylaws or charterChanged its bylaws, charter or fiscal year
5. Jan 23, 2026Company filing · Form 8-K · Restructuring, Reg FDAnnounced job cuts, closures or a restructuring, and shared information with investors“On January 23, 2026, the Board of Directors of Harvard Bioscience, Inc. (the “Company”) approved management’s comprehensive plan, referred to as Project Viking, for the strategic consolidation of its manufacturing operations to improve efficiency and support long-term growth.”
6. Feb 10, 2026Company filing · Form 8-K · ResultsReported its results
7. Mar 6, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On March 6, 2026, Harvard Bioscience, Inc. (the “Company”) entered into an Amended and Restated Employment Agreement (the “Duke Employment Agreement”) with John Duke, the Company’s Chief Executive Officer.”
8. Mar 12, 2026Company filing · Form 8-K · ResultsReported its results
9. Mar 16, 2026 · this disclosureInsider · 3 insiders in a week, 6th time since 2006Director purchased ~$62K of HBIO shares in the open market

What came next

1. Mar 16, 2026Insider · 2 peopleInsiders: 2 purchases (~$50K)
2. Mar 17, 2026Insider · 2 peopleInsiders: 2 purchases (~$90K)
3. May 12, 2026Company filing · Form 8-K · ResultsReported its results
4. Jun 2, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“On June 2, 2026, the stockholders of Harvard Bioscience, Inc. (the “ Company ”) voted to approve the Amended and Restated 2021 Incentive Plan at the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”).”
5. Jun 9, 2026Federal contract · $653K obligatedDepartment of Defense awarded HARVARD BIOSCIENCE INC: $653K obligated to date
6. Jun 12, 2026Federal contract · $61K obligatedDepartment of Defense awarded HARVARD BIOSCIENCE INC: $61K obligated to date

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Harvard Bioscience

For Harvard Bioscience, OQRO holds 4 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its HBIO page.

Other recent filings by William Snider, Director

• SEC Form 4 at Harvard Bioscience (HBIO)Mar 18, 2026

The full history of William Snider, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Harvard Bioscience

• USAspending.gov award recordOct 5, 2026
• USAspending.gov award recordSep 30, 2026
• USAspending.gov award recordJul 29, 2026
• USAspending.gov award recordJul 28, 2026
• USAspending.gov award recordJul 9, 2026
• USAspending.gov award recordJun 12, 2026

Everything OQRO holds on this company is on its HBIO page.